Abstracts by keywords: real world evidence
Demenz stellt eine wachsende globale Herausforderung für die öffentliche Gesundheit dar; die Zahl der Betroffenen wird bis 2030 auf 78 Millionen geschätzt. Mit der steigenden Lebenserwartung nimmt auch die sozioökonomische und gesundheitliche Belastung durch Demenz erheblich zu. Der Typ-2-Diabetes mellitus (T2DM) ist ein gut etablierter Risikofaktor und erhöht die Wahrscheinlichkeit, eine Demenz – einschließlich Alzheimer-Krankheit und vaskulärer Demenz – zu entwickeln, um bis zu 60% [Biessels & Despa, 2018]. Die pathophysiologischen Mechanismen, die T2DM mit Demenz verbinden, umfassen chronische Hyperglykämie, Insulinresis-tenz, zerebrovaskuläre Dysfunktion, Neuroinflammation und oxidativen Stress – alles Faktoren, die zum kognitiven Abbau beitragen [Beeri & Bendlin, 2020]. Trotz intensiver Forschung existieren bislang keine krankheitsmodifizierenden Therapien für Demenz, was die Notwendigkeit unterstreicht, modifizierbare Risikofaktoren sowie pharmakologische Strategien zur Verlangsamung des kognitiven Abbaus zu identifizieren [Livingston et al., 2020].
30.11.2025
Longitudinal analysis of psoriasis, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and chronic bowel disease
Course of the disease and use of medication in chronic inflammatory diseases in Germany
02.04.2023
The malignant tumor disease of diffuse large-cell B-cell lymphoma (DLBCL), which originates from immune cells, is considered the most common non-Hodgkin's lymphoma in adults, with around 30 to 58% (Tilly et. al 2015: p. 116). With a two-year incidence of 3.8 cases per 100,000 inhabitants, it is the most common malignant disease of the lymphatic system in Europe (Sant et al. 2010: 3728). The incidence increases with age, with a median of 70 years (Morton et al. 2006: 265). In addition to an enlargement of the lymph nodes, the spleen can also be affected. Lymphomas often have an aggressive course. If left untreated, DLBCL can be fatal. Due to a high histological, clinical and molecular variability, the mean survival time varies greatly. The 5-year survival rates are given as 60-90% (Ärztezeitung 2021), although survival is worse, especially if there is no response to 1L therapy (AWMF online 2022). In the therapy, among other things, autologous or allogeneic stem cell transplants (STZ) are carried out; the expenses amount to between 107,457 euros and 230,399 euros per patient (Mayerhoff et al. 2019: 126). There are now newly approved treatment options in Germany that are intended to enable patients to survive longer. In August 2018, the treatment method of CAR-T cell therapy (chimeric antigen receptor on T cells) was approved in the European Union after 2L or more lines of therapy. This is a cancer immunotherapy based on genetically modified T cells with synthetic antigen-specific receptors (Srivastava/Riddell 2015: 494). Furthermore, especially in 1L and 2L, immunochemotherapies or classic chemotherapy are used, often in the form of complex treatment regimens and sometimes in combination with rituximab (RTX). Due to these complex treatment options, there is a need for scientific evidence on care.
17.05.2022
Health services research - or in international parlance with comparable meaning "Real World Evidence (RWE) studies", "Health Services Research" or "Health Economics Outcomes Research (HEOR)" are scientific disciplines that address "real patient care" - increasing importance has been predicted for years, especially in the area of pharmaceutical products. Something similar can also be determined for Germany4, both if one follows announcements from politicians and self-administration, discussions on the current Statutory Health Insurance Care Strengthening Act as well as published positions from actors from the medical profession or the pharmaceutical and medical technology industries.